Assertio Beats Investor Suit Over Drug, Merger Claims
An Illinois federal judge Friday dismissed a proposed investor class action claiming Assertio misled shareholders about threats to sales of its arthritis drug Indocin, saying the company's public filings explicitly and...To view the full article, register now.
Already a subscriber? Click here to view full article